A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Antifungal treatment.
- Who it may be relevant to
- Registry conditions: Candidemia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Short-Course Antifungal Therapy vs Standard of Care (14 Day Therapy) for Uncomplicated Candidemia (SCAT)
Overview
The goal of this clinical trial is to assess whether a seven-day course of standard of care (echinocandin) antifungal therapy is non-inferior to a 14-day course of echinocandin antifungal therapy in patients with uncomplicated candidemia in terms of clinical, mycologic, adverse events and all cause mortality.
Interventions
- Drug Antifungal treatment
Short-course antifungal therapy (7 days) versus standard of care antifungal therapy (14 days)
Primary outcome measures
- Eradication of candida from the blood at day 7 or day 14 [Time frame: 14 Days]
Eligibility criteria
Inclusion criteria
- Patients ≥ 18 years of age
- Uncomplicated candidemia (positive blood culture only). No evidence of invasive candidiasis at day 1 or until day 7.
- Received < 5 days of prior antifungal therapy
- Informed Consent for randomization
- Patients that did not consent to randomization have consented to be used as a natural history (controls) and will allow collection of available data from the medical record.
Exclusion criteria
- Inadequate source control (e.g., unable to remove endovascular devices, urinary catheters).
- Invasive candidiasis of any type (e.g., deep seated candidiasis from sources other than blood)
- Abnormal LFTs > 10-fold
- Greater than 5 days of prior antifungal therapy
- Endovascular devices that cannot be removed.
- Immunocompromised patients (AIDS/HIV; solid organ transplant, bone marrow transplant patients, oncology patients receiving chemotherapy, neutropenic patients (ANC of < 1,500 cells/L
- Neutropenic at time of consent (what does this mean)
- Break-through candidemia (people with prior candidemia who relapsed) after treatment with antifungal therapy)
- Unable to provide informed consent from either the patient or legally authorized authority (LAR)
- Expected mortality within 96 hours
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Augusta University — Augusta
Identifiers
NCT: NCT06907992 · MSG 23 · U01CK000692